Subscribe to RSS
Prevalence of Glucose-6-Phosphate Dehydrogenase Deficiency in Newborns in Northeast Mexico
Objective Glucose-6-phosphate dehydrogenase deficiency (G6PDd) is the most common enzymatic disease worldwide and the prevalence is not well established because of the lack of screening. This study aimed to estimate the prevalence of G6PDd in a Hispanic population from Northeast Mexico.
Study Design In this retrospective study, a database was used to analyze the G6PDd in neonates included in the expanded newborn metabolic screening of inherited metabolic disorders during a period of 4 years through the GSP Neonatal G6 kit (PerkinElmer).
Results Among 96,152 (48,462 male) neonates screened for G6PD enzyme activity, a total of 566 (0.58%) cases were deficient for G6PD. Of those 566 patients, 469 (82.8%) attended the second test and the other 97 (17.2%) patients were lost. Of those 469 who did attend, 384 (81.9%) neonates were deficient in the second test and 85 (18.1%) were normal. With the data collected, 384 neonates were confirmed with G6PDd, 348 (88.6%) were male and 36 (11.4%) patients were female. The calculated prevalence for this population was 0.72 cases per 100 male newborns.
Conclusion The prevalence of G6PDd in the Northeastern Mexican population is high. Since migration is increasing in the United States, pediatricians should be aware of the need to search for G6PDd in newborns and the wide clinical manifestations they can present.
The calculated prevalence of glucose-6-phosphate dehydrogenase deficiency in Northeast Mexico is 3.99 cases per 1,000 newborns.
Glucose-6-phosphate dehydrogenase deficiency screenings should be included in all newborn metabolic screenings.
Glucose-6-phosphate dehydrogenase deficiency is a common erythroenzymopathy that must be addressed as a public health concern. To anticipate clinical complications, target population monitoring is required.
Received: 26 May 2021
Accepted: 03 August 2022
Accepted Manuscript online:
17 August 2022
Article published online:
29 December 2022
© 2022. Thieme. All rights reserved.
Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA
- 1 Cappellini MD, Fiorelli G. Glucose-6-phosphate dehydrogenase deficiency. Lancet 2008; 371 (9606): 64-74
- 2 Ronquist G, Theodorsson E. Inherited, non-spherocytic haemolysis due to deficiency of glucose-6-phosphate dehydrogenase. Scand J Clin Lab Invest 2007; 67 (01) 105-111
- 3 Stanton RC. Glucose-6-phosphate dehydrogenase, NADPH, and cell survival. IUBMB Life 2012; 64 (05) 362-369
- 4 Mason PJ, Bautista JM, Gilsanz F. G6PD deficiency: the genotype-phenotype association. [published correction appears in Blood Rev. 2010;24(1):49] Blood Rev 2007; 21 (05) 267-283
- 5 Harcke SJ, Rizzolo D, Harcke HT. G6PD deficiency: an update. JAAPA 2019; 32 (11) 21-26
- 6 Luzzatto L, Nannelli C, Notaro R. Glucose-6-phosphate dehydrogenase deficiency. Hematol Oncol Clin North Am 2016; 30 (02) 373-393
- 7 Zinkham WH, Lenhard Jr RE, Childs B. A deficiency of glucose-6-phosphate dehydrogenase activity in erythrocytes from patients with favism. Bull Johns Hopkins Hosp 1958; 102 (04) 169-175
- 8 Gómez-Manzo S, Marcial-Quino J, Vanoye-Carlo A. et al. Glucose-6-phosphate dehydrogenase: update and analysis of new mutations around the world. Int J Mol Sci 2016; 17 (12) 2069
- 9 Cantú-Reyna C, Santos-Guzmán J, Cruz-Camino H. et al. Glucose-6-phosphate dehydrogenase deficiency incidence in a Hispanic population. J Neonatal Perinatal Med 2019; 12 (02) 203-207
- 10 García-Magallanes N, Luque-Ortega F, Aguilar-Medina EM. et al. Glucose-6-phosphate dehydrogenase deficiency in northern Mexico and description of a novel mutation. J Genet 2014; 93 (02) 325-330
- 11 Monteiro WM, Val FF, Siqueira AM. et al. G6PD deficiency in Latin America: systematic review on prevalence and variants. Mem Inst Oswaldo Cruz 2014; 109 (05) 553-568
- 12 Borrajo GJC. Newborn screening in Latin America: a brief overview of the state of the art. Am J Med Genet C Semin Med Genet 2021; 187 (03) 322-328
- 13 Zamorano-Jiménez CA, Baptista-González HA, Bouchán-Valencia P. et al. Identificación molecular de la glucosa-6-fosfato deshidrogenasa (G6PD) detectada en el tamiz neonatal. Gac Med Mex 2015; 151 (01) 34-41
- 14 Trigo-Madrid M, Díaz-Gallardo J, Mar-Aldana R. et al. Resultados del Programa de Tamiz Neonatal Ampliado y epidemiología perinatal en los servicios de sanidad de la Secretaría de Marina Armada de México. Acta Pediatr Mex 2014; 35 (06) 448-458
- 15 Howes RE, Piel FB, Patil AP. et al. G6PD deficiency prevalence and estimates of affected populations in malaria endemic countries: a geostatistical model-based map. PLoS Med 2012; 9 (11) e1001339
- 16 Fu C, Luo S, Li Q. et al. Newborn screening of glucose-6-phosphate dehydrogenase deficiency in Guangxi, China: determination of optimal cutoff value to identify heterozygous female neonates. Sci Rep 2018; 8 (01) 833
- 17 American Academy of Pediatrics Subcommittee on Hyperbilirubinemia. Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. [published correction appears in Pediatrics. 2004;114(4):1138] Pediatrics 2004; 114 (01) 297-316
- 18 WHO Working Group. Glucose-6-phosphate dehydrogenase deficiency. Bull World Health Organ 1989; 67 (06) 601-611
- 19 Guide to G6PD deficiency rapid diagnostic testing to support P. Vivax radical cure. Geneva, Switzerland: World Health Organization; 2018
- 20 DelFavero JJ, Jnah AJ, Newberry D. Glucose-6-phosphate dehydrogenase deficiency and the benefits of early screening. Neonatal Netw 2020; 39 (05) 270-282
- 21 Therrell BL, Padilla CD, Loeber JG. et al. Current status of newborn screening worldwide: 2015. Semin Perinatol 2015; 39 (03) 171-187
- 22 Koopmans J, Hiraki S, Ross LF. Attitudes and beliefs of pediatricians and genetic counselors regarding testing and screening for CF and G6PD: implications for policy. Am J Med Genet A 2006; 140 (21) 2305-2311